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The following sections represent an overview of
key points from the 2003 Public Health Service
Task Force Recommendations for Use of
Antiretroviral Drugs in Pregnant HIV-1 Infected
Women for Maternal Health and Interventions to
Reduce Perinatal HIV-1 Transmission in the US
(available at www.aidsinfo.nih.gov under guide-
lines, perinatal) and/or the 11th Conference on
Retroviruses and Opportunistic Infections (CROI)
- February 8 - 11, 2004, San Francisco, CA.   
Prevention of Vertical
Transmission of HIV Infection
Efficacy of Antiretroviral Therapy
Mother-to-child transmission (MTCT) may be pre-
vented by treating the mother and/or her baby with
antiretroviral therapy (ART). Studies have shown
a 66% reduction or greater in vertical transmission
with different antiretroviral treatment strategies,
including both mono- and combination therapy.
The first of these studies, initially reported in 1994,
showed that the HIV-1 transmission rate for
infants who received placebo was 22.6%, com-
pared with 7.6% for those who received zidovu-
dine (AZT). This translates into a 66% reduction in
risk for transmission in those who received treat-
ment compared to those who received placebo.
Other studies have shown similar results. One
study compared nevirapine given to women at the
onset of labor and infants at 48-72 hours of life
with a very short regimen of AZT given orally dur-
ing labor and to the infant for the first week of life.
In this study, transmission of HIV among the
infants at six weeks of age was 12% in the nevi-
rapine arm verses 21% in the AZT arm–a reduc-
tion in transmission of nearly 50%. Another study
reports transmission rates of 12.3% for nevirapine
compared with 9.3% with AZT combined with
lamivudine (3TC). In the US, the standard recom-
mendation for infant prophylaxis is six weeks of
AZT, regardless of whether the woman has had
antepartum, intrapartum, or postpartum ART (for
details of AZT dosing in neonates, see perinatal
guidelines website noted in the introduction to this
article). 
It is unclear how intrapartum AZT prophylaxis
works as maternal viral load suppression does not
fully explain the observed efficacy. The efficacy
beyond viral load suppression may be related to
the fact that AZT is metabolized into the active
triphosphate form within the placenta, which has
not been observed with other nucleosides, such
as ddI or ddc. Some concerns relating to the safe
administration of AZT in pregnancy have been
raised with regard to the drug causing disruption in
the maternal-fetal barrier, with subsequent
observed cytotoxic n vitroeffects of AZT on the
human placenta. However, this has not translated
into obvious clinical sequelae in the infant thus far,
and the data as presented above do clearly sup-
port its use in terms of reduction of HIV transmis-
sion to the infant. Whether it relates to increased
risk for preterm labor and premature birth, low
f tal birth weight, or other more serious clinical
events is yet to be determined.
Combination ART appears to have an even
greater effect in reducing HIV transmission.  In
one of these studies, the transmission rate was
10.4% among women who received AZT alone,
3.8% among women who received combination
therapy without protease inhibitors (PIs), and
1.2% among women who received combination
therapy with PIs.  Because of concerns relating to
antiretroviral resistance among infected mothers
and infants exposed to monotherapy, particularly
nevirapine as discussed earlier, the use of combi-
nation therapy may be more prudent in the US
since it is widely available. Counseling women
about the potential for resistance and the long-
term effect it may have for her with regard to future
antiretroviral options is vital and should be taken
into consideration when choosing an appropriate
regimen for her.  For more detailed information on
choosing different strategies in treating pregnant
women with HIV infection, please refer to this
month's Heppigram on page 4.
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Initial Evaluation and Antiretroviral
Considerations for HIV-infected Pregnant
Women with Regard to Safety and
Toxicity 
Initial evaluation of an HIV-infected pregnant
woman should include an assessment of HIV-
1 disease status, including evaluation of the
degree of existing immunodeficiency deter-
mined by CD4 count, the risk for disease pro-
gression determined by the level of plasma
RNA, history of prior or current antiretroviral
therapy, gestational age, and supportive care
needs, and recommendations regarding
options for ART based on the history of previ-
ous treatment. The benefits of ART for a
pregnant woman must always be weighed
against the risk of adverse events to the
woman and the baby. These considerations
must be carefully thought out and discussed
with the patient so that she can make an
informed decision. Many women who have
begun ART before pregnancy require adjust-
ment of the regimen during the pregnancy
due to either (1) intolerance during pregnancy
especially in the first trimester, (2) possible
dosing changes due to physiologic changes
associated with pregnancy, (3) potential long-
and short-term effects of the drug(s) on the
fetus and newborn, and/or (4) discontinuing
agents with potential for reproductive toxicity.
As with all pregnant women, those receiving
ART should be evaluated and closely moni-
tored for hyperglycemia, anemia, and hepatic
toxicity and should be offered optimal nutri-
tional status.
Data are limited regarding the safety of anti-
retroviral drugs in pregnancy and recommen-
dations for use are based on animal toxicity
data, anecdotal experience, registry data,
and clinical trials. Data are conflicting as to
whether the use of combination ART during
pregnancy is associated with preterm deliv-
ery. Until more is known, these women should
be monitored carefully for pregnancy-related
toxicities/complications.  
Toxicities related to nucleoside analog drugs,
such as symptomatic lactic acidosis and
hepatic steatosis, may have a female prepon-
derance, and these conditions have similari-
ties to rare but life-threatening complications
in pregnancy, such as acute fatty liver and
HELLP syndrome (hemolysis, elevated liver
enzymes, low platelets). Whether these con-
ditions are increased during pregnancy
among women treated with nucleosides is
unknown, though there are published case
reports that suggest this may be true. The
clinician should have a low threshold for con-
sidering and screening for any of these men-
tioned toxicities in a pregnant patient on ART.
Among babies born to HIV-infected mothers
taking nucleoside therapy during pregnancy,
there are conflicting data as to whether these
infants are at increased risk for mitochondrial
dysfunction, believed to be the etiology
behind lactic acidosis and hepatic steatosis.
However, this condition, though often fatal
when it occurs in infants, appears to be rare.  
Regarding the use of non-nucleoside reverse
transcriptase inhibitors, the development of
severe nevirapine-associated skin rash has
been reported to be 5.5 to 7.3 times more
common in women than men, and has been
reported in pregnant women. Hepatic toxicity
with systemic symptoms due to nevirapine
was 3.2-fold more common in women than
men. In a summary analysis from 17 clinical
trials of nevirapine use, women with higher
CD4 counts (>250 cells/mm3) were 9.8 times
more likely than women with lower CD4
counts (<250 cells/mm3) to experience symp-
tomatic, rash-associated, nevirapine-related
hepatotoxicity. It is unknown if pregnancy
increases this risk. At the 11th CROI, it was
reported that women were significantly less
likely to have an adverse reaction to nevirap-
i e when it was started during pregnancy
compared to women not pregnant. However,
Martinson, et al reported at CROI that even
though use of nevirapine significantly
reduced vertical transmission, with HIV occur-
ring in only 8.6% of births among 623 women.
Nevirapine-resistant virus occurred in 38.8%
of mothers and in 42.4% of infants.
Although it is known that PIs are associated
with hyperglycemia, new-onset diabetes mel-
litus, exacerbation of existing diabetes, and
diabetic ketoacidosis, it is not known if they
increase the risk of pregnancy-associated
hyperglycemia, and therefore, glucose levels
should be closely monitored in these patients.
Please refer to this month’s HIV 101 on page
6 for a complete list of currently available anti-
retroviral drugs with known safety/toxicity
information for each drug in pregnancy.
Breastfeeding and HIV Transmission Risk
In the US, breastfeeding among HIV-infected
women is not recommended due to risk of
HIV transmission, which occurs at a rate of
about 7 to 14 percent. According to the World
Health Organization's recommendations for
MTCP, when replacement feeding is accept-
able, feasible, affordable, sustainable and
afe, avoidance of all breastfeeding by HIV-
infected mothers is recommended. For infor-
mation pertaining to appropriate recommend-
ed scenarios for HIV-1 resistance testing
among pregnant women and mode of deliv-
ery relating to vertical transmission of HIV,
please refer to the perinatal guidelines cited
in the introduction to this article.
Antiretroviral Pregnancy Registry
The Antiretroviral Pregnancy Registry is
designed to collect observational, nonexperi-
mental data regarding antiretroviral exposure
during pregnancy for the purpose of assess-
ing the potential teratogenicity of the drugs.
The registry does not use patient names, and
the staff tracks birth outcome follow-up infor-
mation. For more information on this registry
please refer to resources on page 4.
Clinical Update on
Lipodystrophy Syndrome
Associated with HIV
Infection and
Antiretroviral Therapy
The reported prevalence of lipodystropy
ranges anywhere from two to 84%, depend-
ing on the definition used and the ease of
recognition among patients and providers.
Tien et alreported the estimated incidence of
lipoatrophy, or fat loss, and lipohypertrophy,
or fat gain, among women with and without
HIV infection from the Women's Interagency
HIV Study (WIHS). The syndrome is evaluat-
ed for by both the participants via question-
naires detailing noticeable body changes and
by the researchers via anthropometric mea-
surements at regular intervals. The authors
performed a 30-month incidence analysis
mong 810 women, 605 of whom were HIV-
infected and 210 of whom were HIV-uninfect-
ed. Overall, among HIV-infected women, the
incidence of lipoatrophy was higher (nearly
double) than that among the uninfected
women after adjusting for age and race,
whereas there was no statistically significant
difference in central lipohypertrophy seen
between the two groups and a lower inci-
dence of peripheral hypertrophy among HIV-
infected women. Their findings suggest that
peripheral and central lipoatrophy associated
with HIV infection appears prevalent among
women and that peripheral lipoatrophy in
combination with central lipohypertrophy is
uncommon.
How different antiretroviral drugs affect the
development of lipodystrophy is still largely
unknown, though thought to be related most
commonly to the use of prolonged PI therapy
with or without specific nucleosides or non-
nucleosides, such as d4T, ddI, ddc or
efavirenz. Murphy et al presented data at
CROI suggesting that patients who received
DDI plus d4T had an increased risk of periph-
eral lipoatrophy over four years and that indi-
navir was associated with lipohypertrophy. In
another study reported at CROI evaluating
whether changing ART can hasten or alter
the lipodystrophy syndrome, the authors
reported no effect over 24 months after
switching patients from a PI to an efavirenz-,
nevirapine-, or abacavir-based regimen.  
Important Drug-drug
Interactions Associated
with Estrogen Use Among
HIV-infected Women on
Antiretroviral Therapy
Ritonavir has a drug-drug interaction with oral
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“Nevirapine-resistant
virus occurred in 38.8%
of mothers and in 42.4%
of infants.”
3contraceptives (OCPs), such as ethinyl estra-
diol, levonorgestrel, norelgestromin, norethin-
drone, and norgestrel, in which the level of
hormone may be decreased enough to cause
contraceptive failure. Thus, this is of consid-
eration in any patient for whom a ritonavir-
boosted regimen is being offered. Increasing
the dose of OCPs and/or suggesting alterna-
tive forms of contraception to the patient may
best handle this interaction. The same inter-
action occurs with amprenavir, though ampre-
navir levels may also decrease when co-
administered with OCPs, thus decreasing the
effect of amprenavir and increasing the risk
for resistant HIV. For another PI, atazanavir, it
is recommended that the lowest effective
dose of OCPs be used, as this drug increas-
es the OCP level. It is recommended that no
OCPs be used in conjunction with nevirapine
due to strong drug-drug interactions. There
does not appear to be any significant drug-
drug interaction with the use of OCPs and any
of the nucleoside reverse transcriptase
inhibitors, efavirenz, delavirdine, saquinavir,
indinavir, or nelfinavir. Of note, there does not
appear to be any significant drug-drug inter-
action with medroxprogsterone acetate
(Depo-Provera®) and antiretrovirals.
Conclusion
The American College of Obstetrics and
Gynecology (ACOG) recommends that all
women of childbearing age–HIV-infected and
HIV-uninfected alike–be offered reproductive
health care as part of routine medical treat-
ment. Both incarcerated women and those liv-
ing in the free world should receive informa-
tion on birth control options, prevention of
sexually transmitted diseases (STDs), prena-
tal vitamins if a pregnancy is desired, risk fac-
tors for HIV infection and other co-morbid
conditions should a pregnancy occur, and
optimal prevention and treatment of these
conditions in order to preserve the overall
health of the woman and her baby. Informing
incarcerated women about these issues is
particularly critical, as they often lack access
to care before and after incarceration. In
1995, the United States Public Health Service
issued recommendations for universal prena-
tal HIV-1 counseling and testing, including
v luntary counseling and testing for all preg-
nant women in the US HIV testing of all
inmates should be encouraged in correctional
settings where reasonable HIV counseling
and treatment can be provided. This option
affords inmates a chance to make positive
changes in their lives and improve their over-
all health while incarcerated. For women iden-
tified as HIV-infected, the focus of care is not
only on assessment of her stage of infection
and antiretroviral options, but also (1) educa-
tion regarding HIV transmission risks to her
baby during pregnancy and breastfeeding, as
well as medical interventions to prevent
MTCT (2) helping her understand and cope
with realistic expectations for a future preg-
nancy, and (3) offering effective contraception
strategies that will optimize her health before,
during, and after such a pregnancy may
occur. These are just some of the complex
psychosocial issues that an HIV-infected
woman may confront. Ultimately, choices
impacting her reproductive health are up to
the woman alone. As health care providers
however, we can facilitate what may be diffi-
cult decisions for our patients by addressing
them with honesty, compassion and respect.
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4SCENARIO #1 
HIV-infected pregnant women who have not received
prior ART
w Pregnant women with HIV infection must receive standard
clinical, immunologic, and virologic evaluation.
Recommendations for initiation and choice of ART should be
based on the same parameters used for persons who are not
pregnant, although the known and unknown risks and benefits
of such therapy during pregnancy must be considered and
discussed.
w The three-part ZDV chemoprophylaxis regimen, initiated
after the first trimester, should be recommended for all preg-
nant women with HIV-infection regardless of antenatal HIV
RNA copy number to reduce the risk for perinatal transmis-
sion.
w The combination of ZDV chemoprophylaxis with additional
ARVs for treatment of HIV infection is recommended for
infected women whose clinical, immunologic or virologic sta-
tus requires treatment or who have HIV RNA over 1,000
copies/mL regardless of clinical or immunologic status.
w Women who are in the first trimester of pregnancy may con-
sider delaying initiation of therapy until after 10-12 weeks'
gestation.
SCENARIO #3 
HIV-infected women in labor who have had no prior 
therapy
w Several effective regimens are available. These include: 
1. Intrapartum intravenous ZDV followed by six weeks of 
ZDV for the newborn; 
2. Oral ZDV and 3TC during labor, followed by one week 
of oral ZDV/3TC for the newborn; 
3. A single dose nevirapine at the onset of labor followed 
by a single dose of nevirapine for the newborn at age 48 
hours*;
4. The two-dose nevirapine regimen combined with 
intrapartum intravenous ZDV and six week ZDV for the 
newborn. 
5. In the immediate postpartum period, the woman should 
have appropriate assessments (e.g., CD4+ count and 
HIV RNA copy number) to determine whether 
antiretroviral therapy is recommended for her own health.
*These recommendations may change due to the high 
rate of nevirapine resistance. Please refer to the 
following guidelines for updates:  
www.cdc.gov/mmwr/preview/mmwrhtml/rr5118a1.htm
SCENARIO #2 
HIV-infected women receiving ART during the current
pregnancy
w HIV-infected women receiving ART for whom pregnancy is
identified after the first trimester should continue therapy. ZDV
should be a component of the antenatal antiretroviral treat-
ment regimen after the first trimester whenever possible,
although this may not always be feasible.
w For women receiving ART for whom pregnancy is recog-
nized during the first trimester, the woman should be coun-
seled regarding the benefits and potential risks of ARV admin-
istration during this period, and continuation of therapy should
be considered. If therapy is discontinued during the first
trimester, all drugs should be stopped and reintroduced simul-
taneously to avoid the development of drug resistance.
w Regardless of the antepartum ARV regimen, ZDV adminis-
tration is recommended during the intrapartum period and for
the newborn.
SCENARIO #4 
Infants born to mothers who have received no ART dur-
ing pregnancy or intrapartum
w The six-week neonatal ZDV component of the ZDV chemo-
prophylactic regimen should be discussed with the mother
and offered for the newborn.
w ZDV should be initiated as soon as possible after delivery -
preferably within six-12 hours of birth.
w Some clinicians may choose to use ZDV in combination
with other antiretroviral drugs, particularly if the mother is
known or suspected to have ZDV-resistant virus. However,
the efficacy of this approach for prevention of transmission
has not been proven in clinical trials, and appropriate dosing
regimens for neonates are incompletely defined for many
drugs.
w In the immediate postpartum period, the woman should
undergo appropriate assessments (e.g., CD4+ count and HIV
RNA copy number) to determine if antiretroviral therapy is
required for her own health. The infant should undergo early
diagnostic testing so that if HIV-infected, treatment can be ini-
tiated as soon as possible.
Note: Discussion of treatment options and recommendations
should be noncoercive, and the final decision regarding the
use of antiretroviral drugs is the responsibility of the woman. A
decision not to accept treatment with ZDV or other drugs
should not result in punitive action or denial of care. Use of
ZDV should not be denied to a woman who wishes to mini-
mize exposure of the fetus to other antiretroviral drugs and
who therefore chooses to receive only ZDV during pregnancy
to reduce the risk for perinatal transmission.
HEPPigram: Clinical Scenarios and Recommendations for the Use of
Antiretroviral Drugs to Reduce Perinatal HIV-1 Transmission
Adapted from the Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal
Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, November 26, 2003 
http://www.aidsinfo.nih.gov/guidelines/perinatal\PER_112603.html#table3
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Dear Correctional Colleagues:
In keeping with HEPP Report tradition, the treatment of HIV-infected women is the focus
of our May issue. I'm especially pleased to present Dr. Beth Weaver's report on mother-to-child
transmission prevention (MTCP) in this issue. She provides updated guidelines on MTCP, but
it's worth noting that these guidelines change rapidly. For example, it is highly likely that treat-
ment of the HIV-infected woman presenting during labor will be modified to short course combi-
nation therapy (such as nevirapine and combivir, together, for at least one month following
delivery), since single-dose nevirapine has been associated with high rates of resistance due to
the long "tail" of detectable drug levels following administration. The best course to follow when
confronted with lipodystrophy in an HIV-infected woman is, as yet, uncertain. Dr. Weaver pro-
vides a review of the most recent revelations related to this topic, gleaned from the February
2004 CROI conference. And, interestingly enough, this issue of HEPP Report also includes a
discussion of contraception and antiretrovirals. Thus we are once again made aware that HIV-
infected women are vibrant, sexually active and often still desire to have children. 
We need to pause, in this month of that celebrates maternity, to consider the prevalence of HIV
infection among pregnant women all over the world. Just a few statistics of note: The preva-
lence of HIV infection among pregnant women in Bostwana is 32%. In Swaziland, the rate is
40%. In South Africa the rate is 50 %. In Zambia the rate is 69%. These statistics are sobering
–and remind us that we should do all that we can to prevent the further transmission of HIV
infection to babies, no matter what country we call home. 
Of course, neither sex nor pregnancy are events meant to occur during incarceration. We
therefore bring you these updates so that you can better plan your care of women patients as
they are being released back to the community. The fact is, your patients often resume their
lives where they left off (without restarting illicit drug use, we hope). I always tell my soon-to-be-
released patients to have more than one plan - Plan A and Plan B. Even though they may not
be planning to get pregnant, I have a discussion with them about how best to manage their
pregnancy, should it occur. The good news that all of our patients deserve to hear is that HIV
transmission to the newborn does not have to happen. Therefore, as you are planning ahead
for your Mother's Day celebrations, (May 9th this year, in case you were wondering!) do give
some thought to future generations of children who will thank you for teaching your patients
about Plan B. 
As always, we thank our readership for their interest in HEPP Report and we welcome your
comments. 
Sincerely,
A. S. De Groot, MD
Letter from the Editor
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6Antiretroviral 
drug
Abacavir 
(Ziagen, ABC)
Didanosine 
(Videx, ddI)
Emtricitabine
(Emtriva, FTC)
Lamivudine 
(Epivir, 3TC)
Stavudine 
(Zerit, d4T)
Tenofovir DF
(Viread)
Zalcitabine 
(HIVID, ddC)
Zidovudine
(Retrovir, 
AZT, ZDV)
Delavirdine
(Rescriptor)
Efavirenz 
(Sustiva)
Nevirapine
(Viramune)
Amprenavir
(Agenerase)
Atazanavir
Fosamprenavir
(Lexiva)
Indinavir 
(Crixivan)
Lopinavir/
Ritonavir
(Kaletra)
Nelfinavir
(Viracept)
Ritonavir 
(Norvir)
Saquinavir
(Fortovase)
Enfuvirtide
(Fuzeon)
FDA pregnancy
category †
C
B
B
C
C
B
C
C
C
C
C
C
B
C
C
C
B
B
B
B
Placental passage 
(newborn: mother drug ratio)
Yes (rats)
Yes (human) [0.5]
Unknown
Yes (human) [~1.0]
Yes (rhesus monkey) [0.76]
Yes (rat and monkey)
Yes (rhesus monkey) [0.30-
0.50]
Yes (human) [0.85]
Unknown
Yes (cynomologus monkey, rat,
rabbit)[~1.0]
Yes (human)[~1.0]
Unknown
Unknown
Unknown
Minimal (humans)
Unknown
Minimal (humans)
Minimal (humans)
Minimal (humans)
Unknown
Long-term animal 
carcinogenicity studies
Positive (malignant and non-malignant
tumors of liver, thyroid in female rats,
and preputial and clitoral gland 
of mice and rats)
Negative (no tumors, 
lifetime rodent study)
Not completed
Negative (no tumors, 
lifetime rodent study)
Positive (mice and rats, at very high
dose exposure, liver and 
bladder tumors)
Not completed
Positive (rodent, thymic lymphomas)
Positive (rodent, noninvasive vaginal
epithelial tumors)
Positive (hepatocellular adenomas and
carcinomas in male and female mice but
not rats, bladder tumors in male mice)
Positive (increased hepatocellular ade-
nomas and carcinomas and pulmonary
alveolar/bronchiolar adenomas in female
but not male mice)
Positive (hepatocellular adenomas and
carcinomas in mice and rats)
Positive (hepatocellular adenomas and
carcinomas in male mice and rats)
Not Completed
Positive (increased benign and malig-
nant liver tumors in male rodents)
Positive (thyroid adenomas in male rats
at highest dose)
Not Completed
Positive (thyroid follicular adenomas and
carcinomas in rats)
Positive (rodent, liver adenomas and
carcinomas in male mice)
Not completed
Not Done
Animal teratogen 
studies
Positive (rodent anasarca and
keletal malformations at 1000
mg/kg (35x human exposure)
during organogenesis; 
not seen in rabbits)
Negative
Negative
Negative
Negative (but sternal bone 
calcium decreases in rodents)
Negative (osteomalacia when
given to juvenile animals 
at high doses)
Positive (rodent-hydrocephalus
at high dose)
Positive (rodent-near 
lethal dose)
Positive (rodent-ventricular 
septal defect)
Positive (cynomologus monkey-
anencephaly, anophthalmia,
microophthalmia)
Negative
Negative (but deficient ossifica-
tion and thymic elongation in
rats and rabbits)
Negative
Negative (deficient ossification
with amprenavir but not 
fosamprenavir)
Negative (but extra ribs 
in rodents)
Negative (but delayed skeletal
ossification and increase in
skeletal variations in rats at
maternally toxic doses)
Negative
Negative (but cryptorchidism 
in rodents)
Negative 
Negative
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Fusion inhibitors
FDA pregnancy categories: 
A. Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is
no evidence of risk during later trimesters); 
B. Animal reproductive studies fail to demonstrate a risk to the fetus and adequate and well-controlled studies of pregnant women have not been
conducted; 
C. Safety in human pregnancy has not been determined, animal studies are either positive for fetal risk or have not been conducted, and the drug
should not be used unless the potential benefit outweighs the potential risk to the fetus.
Protease inhibitors
Non-nucleoside reverse transcriptase inhibitors
Nucleoside and nucleotide analogue reverse transcriptase inhibitors
HIV 101: Preclinical and Clinical Data Relevant to the Use of Antiretrovirals in Pregnancy
7Mali continues to rank among the few sub-Saharan African countries
with a low prevalence of HIV/AIDS in the general population.
UNAIDS estimated at yearend 2001 that 110,000 adults and children
in Mali were living with HIV/AIDS, with an adult prevalence of 1.7
percent–comparable to that of the US. Yet a suspected higher preva-
lence in "bridge" populations, such as long-distance truck drivers,
ambulatory vendors, and female sex workers portends a wider epi-
demic. UNAIDS also estimates that 55 percent of adults living with
HIV/AIDS in Mali are women.
The Bollé Correctional and Rehabilitation Facility for Women and
Girls, (Centre Spécialisé de Détention de Réeducation et de
Réinsértion pour Femmes et Filles Mineurs de Bollé), which lies on
the outskirts of the capitol city of Bamako, Mali, is one of seven pris-
ons in the nation. Bollé, the largest facility for female inmates in the
country, opened its doors in 1998, and houses from 50 to 70 women
and girls at a time. Malians make up the majority of the detainees;
however, nearly all West African countries are represented.  
Apart from the lack of resources and medical care, the Bollé facility
greatly differs from its US counterparts in that the inmates are entire-
ly self-sufficient. In the past, non-governmental organizations were
able to support the prison with donations of food and medical sup-
plies, but prison director Diarra Assétou Kouyaté said that these
organizations could no longer afford to provide assistance. Trades
such as cloth-dying, sewing, and soapmaking not only afford these
women with skills to survive once they are released, but also func-
tion as a means of economic support for the facility. Children of the
inmates are permitted to live at the prison until the age of four, and
are completely in their mother's charge since the prison cannot
afford to feed, clothe, or provide medicines for them.
Relative to the US, there are very few women imprisoned in Mali.
Kouyaté, who toured prisons in the US several years ago, explained
that "in Mali the women are well-behaved." While the Bollé prison is
recognized as being one of the best correctional facilities in West
Africa for preserving the dignity of inmates, Kouyaté stated bluntly
that "this is no hotel."  Surprisingly, most of the women are not incar-
cerated for prostitution or drug-related charges. They are serving
sentences for infanticide. The influx of young women to urban areas
is fueled by a desire to earn a better living and find a husband. Many
of them, however, end up involved in prostitution. Faced with an
unwanted pregnancy or lack of financial means to provide for the
baby, the woman may resort to "the worst of crimes," said Kouyaté.
The other small percentage of crimes for which the women are con-
victed include involuntary homicide, fraud, and having abandoned
their families.  
HIV Testing
Routine HIV testing does not exist in the women's prison.
Occasionally, HIV tests are  performed when a woman is chronical-
ly ill, or goes to the hospital to have a child or undergo surgery.
Accordingly, HIV prevalence is unknown. As in Malian society, AIDS
remains a taboo subject in the correctional environment. "Because
of the stigma associated with AIDS in Mali, the women here simply
do not believe the facts about AIDS," said Kouyaté. Not surprisingly,
most incarcerated women here would likely refuse to be tested even
if given the opportunity. The administration has always made con-
certed efforts to keep testing as discreet as possible but personal
information travels fast inside the prison walls. "These women are
very perceptive," Kouyaté said. "They know what goes on here bet-
ter than the staff does." The Bollé prison does not have recourse to
legislation on informed consent or any laws regarding HIV testing in
the correctional setting. Upon further investigation of what is an
extremely delicate–but not a litigious–issue in Malian corrections,
Kouyaté acknowledged the need for protocols for a confidential and
effective testing system. 
Compassionate Release
As a general rule, prisoners who are confirmed to be HIV-infected
are sent to appear before a district judge and are routinely granted
compassionate release. "We simply don't have the means to provide
care and treatment for them…These women are not left to die in
prison," said Kouyaté. Antibiotics for treatment of OIs are sorely
needed. Not only are antiretrovirals (ARVs) not available on the
ins de, but the medical staff is also not trained in pre- or post-test
counseling. By the time a case of HIV is suspected by the medical
staff, the woman has usually progressed to full-blown AIDS. Since
1999, there have been six women who have tested positive for HIV
at Bollé, five of whom died of AIDS following compassionate release.
The sixth woman, who has not developed full-blown AIDS, is being
treated with ARVs and followed by CESAC (Centre de Soins,
d'Animation et de Conseil), a Malian governmental organization that
provides HIV/AIDS prevention, treatment and counseling. Created in
1996, one of the organization's primary objectives is the prevention
of mother-to-child transmission of the virus. Following release by the
judge, a prisoner who tests positive for HIV is referred to this center
for treatment and follow-up. 
Access
Supply, distribution and cost constitute the triumvirate of challenges
in the fight against the AIDS pandemic in Africa. Currently, the fol-
lowing ARVs are approved for treatment of HIV infection in Mali:
didanoside, zidovudine, lamivudine, stavudine, nevirapine,
efavirenz, nelfinavir and indinavir. There are not enough of these
medications, however,  to keep them in stock at the pharmacy, which
renders treatment interruption inevitable. An infrastructure for dis-
pensing these drugs does not exist, nor does the personnel for dis-
tributing them. Furthermore, difficulties in accessing transportation to
and from the hospital or clinic for treatment and proper follow-up are
realities in Mali.    
Cost reduction of ARVs–the issue that seems to be dominating
recent discourse on AIDS in the developing world–is a key factor for
making treatment more accessible to the population. IMAARV
(Initiative Malienne d'Accès aux Antirétroviraux) is a program
financed by the state and private sector whereby eligible individuals
can receive ARVs and medications for opportunistic infections at
reduced cost since they come from bulk suppliers. Although
IMAARV has committed to instituting two-year treatment programs
that aim to improve the quantity and quality of available ART, cost
remains a formidable barrier. For example, 50 percent cost reduction
in ARVs translates into about 45,000 CFA/month (about $88 (US)).
Yet, given that the cost is higher than the average monthly house-
hold income, ARVs are still inaccessible to 90 percent of the HIV-
infected population of Mali.  
Conclusion
Today, the AIDS situation in Mali is not as dire as it is in some African
nations. However, significant seasonal migration of agricultural
workers to Senegal, Côte d'Ivoire, (which has the highest HIV preva-
lence in West Africa), and France during Mali's off-agricultural sea-
son could have a serious effect on the spread of HIV in Mali in years
to come. The past decade bears witness to the fact that no country
is insulated from the risk of the epidemic. The Bollé prison has many
stories to tell about the women for whom release into the free world
has equated further confinement by AIDS. The prison medical staff
shared only a handful of these inmates' stories, each one unique but
with the same tragic ending. The hope is that one day these young
women will re-enter the free world as healthier and more confident
individuals; this can be accomplished with the help of governments,
NGOs, and individuals committing to care more–and to care sooner. 
Disclosures: *Nothing to disclose.
Julia Noguchi*, Managing Editor, HEPP Report
Spotlight: HIV Management in a Malian Women's Prison
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NCCHC: Clinical Updates in
Correctional Health Care
May 22-25, 2004
Hyatt Regency
Chicago, IL
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
9th Northeast Correctional
Health Care Conference
May 26, 2004
Sturbridge Host Hotel
Sturbridge, MA
Contact: Pharmaceutical
Strategies, Inc.
Call: 781.279.2254
Fax: 781.279.2977
Email: rduhaime@icg-ps.com
2nd Annual Clinical Care
Options for Hepatitis
Symposium
June 24, 2004
Ritz-Carlton Niguel
Dana Point, CA
Designed for participants to syn-
thesize the year's scientific and
medical advances and discuss
state-of-the art treatment strate-
gies with leading experts and 
colleagues in a setting that is 
conducive to both formal learning
and informal networking.
Call: 800.878.6260
Email: dperalta@
mtgessentials.com
Visit: http://clinicaloptions.com/
go/ccohep2004
XV International AIDS
Conference
July 11-16, 2004
Bangkok, Thailand
The International AIDS Society, 
in partnership with the Thai
Ministry of Public Health and in
collaboration with the international
Community and UNAIDS invites
you to join this extraordinary 
gathering to advance another 
milestone in the global fight
against HIV/AIDS.
Register online at:
http://www.aids2004.org/
Save the 
Dates
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Valacyclovir Prevents Transmission of HSV
HSV (Herpes Simplex Virus) is the leading cause
of genital ulcers in both developed and develop-
ing countries. According to a recent study on
valacyclovir given once daily to a patient with
genital herpes, valacyclovir significantly reduces
the rate of HSV transmission. This study involved
a prospective, randomized, placebo-controlled
trial of valacyclovir (500 mg/day for 8 months) in
1,484 immunocompetent, heterosexual, monoga-
mous couples that were discordant for herpes
simplex virus-2 (HSV-2) symptomatic genital
infection. A subset analysis was done in 89
patients to determine the effect of valacyclovir on
viral shedding using HSV polymerase chain reac-
tion (PCR) analysis of genital swab specimens.
As demonstrated in the study, viral shedding is
notably reduced in the source patient. The poten-
tial application of this information is important for
couples that are discordant for HSV. However,
this may have an even more important applica-
tion for reducing transmission of HIV infection, as
these ulcers have high concentrations of HIV in
co-infected patients. 
Corey L, Wald A, Patel R, et al. NEJM.
2004;350:11-20
FDA Approves First Oral Fluid Based Rapid
HIV Test Kit
The FDA has approved the use of oral fluid sam-
ples with a rapid HIV diagnostic test kit that pro-
vides screening results with over 99 percent
accuracy in as little as 20 minutes. Until now, all
rapid HIV tests required the use of blood in order
to get such rapid results. In addition to simplifying
the testing process and precluding the need for a
blood sample, use of the oral collection compo-
nent reduces risk to healthcare workers perform-
ing the test by reducing exposure to blood and
sharps. The Centers for Disease Control and
Prevention (CDC) has estimated that one fourth
of the approximately 900,000 HIV-infected peo-
ple in the US are not aware that they are infect-
ed. 
NATAP - www.natap.org, March 26, 2004
HAART Treatment During Acute HIV-Infection
Not Recommended
A recent joint study from Australia and the US
concluded that antiretroviral treatment of primary
HIV infection (PHI) may not be clinically justified
on the basis of current evidence. Where does this
leave the clinician who has identified a patient as
acutely infected with HIV? In some regards, the
question of when to treat in PHI is similar to those
patients identified with established infection; how-
ever, at the start of the disease course there is
the possibility of proportionally larger benefits,
making this an important question to answer.
Ba ed on the currently published data, there is no
clear evidence that patients with access to ART
have any greater clinical benefit if therapy is intro-
duced immediately during or prior to their sero-
conversion illness, nor are there comparative
data to suggest that short-term use of HAART
during PHI can alter future disease progression.
Currently, no evidence from these studies sug-
gests that therapy during PHI results in a reduc-
tion in clinical progression compared with use of
effective therapy in later disease. 
Smith, Don E. et al. AIDS: Volume 18(5) 26
March 2004 pp 709-718.
Study: Detecting Human Papillomavirus DNA
in Men
A study presented at the Human Papillomavirus
2002 International Conference in Paris evaluated
methods for detection of genital human papillo-
mavirus (HPV) DNA in men. In this study, sam-
ples were obtained from three consecutive
groups of 10 men attending a sexually transmit-
ted disease clinic by use of (1) a saline-wetted
Dacron swab alone, (2) a saline-wetted cyto-
brush, or (3) emery paper (600A-grit Wetordry
T i-M-ite; 3M) abrasion followed by a saline-wet-
ted Dacron swab. By use of a polymerase chain
reaction-based assay, 45% of emery-paper sam-
pl s were found to be positive for -globin, com-
pared with 23% of swab-alone and 0% of cyto-
b ush samples. Subsequently, emery paper and
saline-wetted Dacron swabs were used to obtain
penile shaft, glans, foreskin, and scrotum sam-
ples from 318 male university students. Urine
samples were also obtained. Of 1323 samples
tested, 1288 (97%) were found to be positive for
-globin. HPV DNA was detected in samples from
104 men (33%): 24% from the penile shaft, 16%
from the glans, 28% from the foreskin, 17% from
the scrotum, and 6% in urine. The HPV preva-
lence was similar for circumcised and uncircum-
cised men. Testing multiple sites increased the
number of men for whom HPV DNA was detect-
ed.
Bethany A. Weaver et al. Evaluation of Genital
Sites and Sampling Techniques for Detection of
Human Papillomavirus DNA in Men. JID
2004;189:677-685.
Inside News
Resources
HIV InSite Knowledge Base, University of San
Francisco
http://hivinsite.ucsf.edu
AIDS Alliance for Children, Youth & Families
www.aidsalliance.org/aids_alliance/index.html
The National Commission on Correctional
Health Care
www.ncchc.org/
Women, Children, and HIV
http://womenchildrenhiv.org/
Albany Medical Center's AIDS Program
www.amc.edu/patient/hiv/hiv_correctional.htm
US Dept. of Health and Human Services:
Services to People with HIV in Correctional
Settings
http://hab.hrsa.gov/special/corrections_index.htm
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through November 30, 2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. A 25 year-old pregnant women with HIV received intrapartum
prophylaxis therapy during the first trimester but then discontin-
ued therapy after 12 weeks of gestation. It is recommended that
she:
a) start an entirely new regimen
b) resume her old regimen, reintroducing one drug at a time
c) reintroduce all drugs simultaneously 
d) stop all drugs and receive a single dose of nevirapine at 
the onset of labor
2. An initial evaluation of an HIV-infected pregnant woman should
include an evaluation of:
a) CD4 cell count
b) history of prior or current ART
c) level of plasma RNA 
d) gestational age
e) supportive care needs 
f) options for ART based on the history of previous treatment
g) all of the above
3. Protease inhibitors that have a drug-drug interaction with oral
contraceptives include:
a) indinavir and nelfinavir
b) amprenavir and ritonavir
c) atazanavir and ritonavir
d) amprenavir and indinavir
4. For HIV-infected women in labor who have had no prior anti-
retroviral therapy, possible regimens may include:
a) oral ZDV and 3TC during labor, followed by one week of 
oral ZDV/3TC for the newborn
b) a single dose of nevirapine at the onset of labor followed 
by a single dose of nevirapine for the newborn at age 48 
hours
c) a only
d) a and b
e) none of the above
5. Studies have shown that hepatic toxicity with systemic symp-
toms due to nevirapine were more than three times more com-
mon in women than in men. True or False.
a) True
b) False
6. According to a recent study, the percentage of nevirapine-
resistant virus that occurred in mothers was:
a) less than one-third
b) greater than one-third
c) one-half
d) greater than half
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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